Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Provenge Nod Lifts Spirits And Stocks, But Also Sets High Bar For Success

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Approval of Dendreon's Provenge is a major achievement and a shot in the arm for the growing field of therapeutic cancer vaccines, but it also serves as a reminder of the high bar for clinical and regulatory success in uncharted territory

You may also be interested in...

Dendreon Readies For Next Provenge Hurdles: Supply And Reimbursement

Having gotten over the hurdle of FDA approval with the market's first therapeutic cancer vaccine, Dendreon now faces the challenge of getting Provenge to the market. Already the company is also signaling that supply is unlikely to match demand in the near term

Provenge Tide Lifts All Immunotherapies; Price Cheers Investors

Analysts scramble to revise revenue forecasts upward after Dendreon releases high-end price and plans to go it alone in Europe

Antigenics Pulls Oncophage Application Following CHMP Negative Opinion

Cancer vaccine is approved for renal cell carcinoma in Russia, but still has not launched there due to prolonged reimbursement talks.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts